Trial Outcomes & Findings for Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) (NCT NCT00727259)

NCT ID: NCT00727259

Last Updated: 2015-04-29

Results Overview

Patient satisfaction for each item on the questionnaires was rated on a scale from 0 (not satisfied) to 7 (very satisfied).

Recruitment status

COMPLETED

Target enrollment

1995 participants

Primary outcome timeframe

The patient was instructed to answer and return by mail the first self-questionnaire after 1 month of treatment and the second one after 3 months of treatment.

Results posted on

2015-04-29

Participant Flow

Enrolled: 1995 subjects; all questionnaires were returned for 940 subjects.

Participant milestones

Participant milestones
Measure
Patients With Chronic Hepatitis C
Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
Overall Study
STARTED
1995
Overall Study
COMPLETED
940
Overall Study
NOT COMPLETED
1055

Reasons for withdrawal

Reasons for withdrawal
Measure
Patients With Chronic Hepatitis C
Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
Overall Study
Not all questionnaires completed
1055

Baseline Characteristics

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients With Chronic Hepatitis C
n=940 Participants
Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol. Results presented concern only participants with all questionnaires returned (940).
Age, Continuous
47.50 years
STANDARD_DEVIATION 12.34 • n=5 Participants
Sex/Gender, Customized
Female
323 Participants
n=5 Participants
Sex/Gender, Customized
Male
616 Participants
n=5 Participants
Sex/Gender, Customized
Missing data
1 Participants
n=5 Participants
Region of Enrollment
France
940 Participants
n=5 Participants

PRIMARY outcome

Timeframe: The patient was instructed to answer and return by mail the first self-questionnaire after 1 month of treatment and the second one after 3 months of treatment.

Population: Both patient questionnaires were returned by 940 subjects. However, some items were not rated on the returned questionnaires. The missing data for questionnaire items range from 24 subjects to 72 subjects.

Patient satisfaction for each item on the questionnaires was rated on a scale from 0 (not satisfied) to 7 (very satisfied).

Outcome measures

Outcome measures
Measure
After 1 Month of Treatment
n=940 Participants
Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
After 3 Months of Treatment
n=940 Participants
Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
Time required for the preparation of the injection
5.49 satisfaction rating from 0-7
Standard Deviation 1.52
5.84 satisfaction rating from 0-7
Standard Deviation 1.32
Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
Ease of preparation of the Pen
5.48 satisfaction rating from 0-7
Standard Deviation 1.74
5.91 satisfaction rating from 0-7
Standard Deviation 1.41
Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
Simplicity of adjustment of the injected dose
5.74 satisfaction rating from 0-7
Standard Deviation 1.71
6.08 satisfaction rating from 0-7
Standard Deviation 1.41
Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
Ease of injection
5.89 satisfaction rating from 0-7
Standard Deviation 1.46
6.00 satisfaction rating from 0-7
Standard Deviation 1.37
Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
Characteristics of the needle
6.14 satisfaction rating from 0-7
Standard Deviation 1.25
6.25 satisfaction rating from 0-7
Standard Deviation 1.21
Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
Overall satisfaction with the system of injection
5.99 satisfaction rating from 0-7
Standard Deviation 1.73
6.04 satisfaction rating from 0-7
Standard Deviation 1.32

Adverse Events

Patients With Chronic Hepatitis C

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Results disclosure agreements

  • Principal investigator is a sponsor employee Any publication or communication (written or oral) could be performed by the Principal Investigator only after written approval from Schering-Plough.
  • Publication restrictions are in place

Restriction type: OTHER